Journal of Clinical Oncology, Vol 15, 1118-1122, Copyright © 1997 by American Society of Clinical Oncology
Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study
A Rueda, E Alba, N Ribelles, I Sevilla, I Ruiz and J Miramon
Oncology Section, Hospital Universitario, Malaga, Spain.
PURPOSE: Chemotherapy is the standard treatment in advanced Hodgkin's
lymphoma and a therapeutic alternative for early stages. Although
polychemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) is equivalent or superior to mechloretamine, vincristine,
procarbazine, and prednisone (MOPP) in advanced disease, no series have
been published using ABVD without associated radiotherapy in early stages.
We report the results obtained with the administration of six cycles of
ABVD alone in clinical stage I and II disease. PATIENTS AND METHODS: From
January 1990 to October 1994, 23 patients with stage I or II Hodgkin's
lymphoma were treated with six cycles of ABVD; six patients who met the
criteria for mediastinal bulky disease also received radiotherapy to the
mediastinum. RESULTS: After six cycles, 20 complete responses (CRs) and
three partial responses (PRs), which became CRs after radiotherapy, were
obtained. Toxicity was moderate and manageable. With a median follow-up
duration of 37 months (range, 12 to 75), three patients have relapsed and
one has died. Overall and progression-free survival rates at 42 months are
95% and 84%, respectively. CONCLUSION: Six cycles of ABVD are effective and
safe in the treatment of stage I and II Hodgkin's lymphoma, at least in the
short term, but long-term observation data are not yet available.
This article has been cited by other articles:
|
|
|
|
 
A. Rueda Dominguez, A. Marquez, J. Guma, M. Llanos, J. Herrero, M. A. de las Nieves, J. Miramon, and E. Alba
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study
Ann. Onc.,
December 1, 2004;
15(12):
1798 - 1804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Straus, C. S. Portlock, J. Qin, J. Myers, A. D. Zelenetz, C. Moskowitz, A. Noy, A. Goy, and J. Yahalom
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
Blood,
December 1, 2004;
104(12):
3483 - 3489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Germann, F. Goffinet, and F. Goldwasser
Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients
Ann. Onc.,
January 1, 2004;
15(1):
146 - 150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Canellos and D. Niedzwiecki
Long-Term Follow-up of Hodgkin's Disease Trial
N. Engl. J. Med.,
May 2, 2002;
346(18):
1417 - 1418.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz
Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease
J. Clin. Oncol.,
November 1, 1999;
17(11):
3577 - 3585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Wirth, M. Chao, J. Corry, C. Laidlaw, K. Yuen, G. Ryan, D. Byram, S. Davis, J. Kiffer, G. Quong, et al.
Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients
J. Clin. Oncol.,
January 1, 1999;
17(1):
230 - 230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
